1
|
Badawy MT, Sobeh M, Xiao J, Farag MA. Androstenedione (a Natural Steroid and a Drug Supplement): A Comprehensive Review of Its Consumption, Metabolism, Health Effects, and Toxicity with Sex Differences. Molecules 2021; 26:6210. [PMID: 34684800 PMCID: PMC8539210 DOI: 10.3390/molecules26206210] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 09/25/2021] [Accepted: 09/27/2021] [Indexed: 02/05/2023] Open
Abstract
Androstenedione is a steroidal hormone produced in male and female gonads, as well as in the adrenal glands, and it is known for its key role in the production of estrogen and testosterone. Androstenedione is also sold as an oral supplement, that is being utilized to increase testosterone levels. Simply known as "andro" by athletes, it is commonly touted as a natural alternative to anabolic steroids. By boosting testosterone levels, it is thought to be an enhancer for athletic performance, build body muscles, reduce fats, increase energy, maintain healthy RBCs, and increase sexual performance. Nevertheless, several of these effects are not yet scientifically proven. Though commonly used as a supplement for body building, it is listed among performance-enhancing drugs (PEDs) which is banned by the World Anti-Doping Agency, as well as the International Olympic Committee. This review focuses on the action mechanism behind androstenedione's health effects, and further side effects including clinical features, populations at risk, pharmacokinetics, metabolism, and toxicokinetics. A review of androstenedione regulation in drug doping is also presented.
Collapse
Affiliation(s)
- Marwa T. Badawy
- Department of Biology, School of Sciences and Engineering, The American University in Cairo, New Cairo 11835, Egypt;
| | - Mansour Sobeh
- AgroBioSciences, Mohammed VI Polytechnic University, Lot 660, Hay Moulay Rachid, Ben-Guerir 43150, Morocco
| | - Jianbo Xiao
- International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China;
- Department of Analytical Chemistry and Food Science, Faculty of Food Science and Technology, University of Vigo, E-36310 Vigo, Spain
| | - Mohamed A. Farag
- Pharmacognosy Department, College of Pharmacy, Cairo University, Kasr el Aini St., Cairo P.B. 11562, Egypt
- Chemistry Department, School of Sciences Engineering, The American University in Cairo, New Cairo 11835, Egypt
| |
Collapse
|
2
|
Kim C, Ross I, Sprando R, Johnson W, Sahu S, Flynn T, Wiesenfeld P, Collins T, O'Neilll R, Sapienza P. Distribution of androstenedione and its effects on total free fatty acids in pregnant rats. Toxicol Ind Health 2016; 23:65-74. [DOI: 10.1177/0748233707076774] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Androstenedione, an anabolic steroid used to enhance athletic performance, was administered in corn oil by gastric intubation once daily in the morning to nonpregnant female rats at a dose of 5 or 60mg/kg/day, beginning two weeks before mating and continuing through gestation day (GD) 19. On GD 20, the distribution of androstenedione and other steroid metabolites was investigated in the maternal plasma and target organs, including brain and liver. The concentration of estradiol in plasma approached a statistically significant increase after treatment as compared with the controls, whereas the levels of androstenedione, testosterone and progesterone were not significantly different from the controls. In the liver, the concentrations of androstenedione and estradiol only were increased in a dose-related manner. None of these steroids was detectable in the brain. Androstenedione treatment also produced changes in the level of selected free fatty acids (FFAs) in the maternal blood, brain, liver and fetal brain. The concentrations of palmitic acid (16:0) and stearic acid (18:0) in the plasma were not significantly different between the controls and treated rats. However, oleic acid (18:1), linoleic acid (18:2) and docosahexaenoic acid (DHA, 22:6) were 17.94 ± 2.06 μg/ml, 24.23 ± 2.42 μg/ml and 4.08 ± 0.53 μg/ml, respectively, in the controls, and none of these fatty acids was detectable in the treated plasma. On the other hand, palmitic, stearic, oleic, linoleic and DHA were present in both control and treated livers. Among the FFAs in liver, linoleic and DHA were increased 87% and 169%, respectively, over controls. Palmitic, stearic and oleic acids were not significantly affected by the 60 mg/kg treatment. These were present in both control maternal and fetal brains, whereas linoleic acid was found only in fetal brain control. DHA was present only in the control maternal brain (0.02 ± 0.02 μg/mg protein) and fetal brain (0.24 ± 0.15 μg/mg protein). The results indicated that androstenedione exhibits significantly different effects on the FFA composition among target organs during pregnancy.
Collapse
Affiliation(s)
- C.S. Kim
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment,
| | - I.A. Ross
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - R.L. Sprando
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - W.D. Johnson
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - S.C. Sahu
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - T.J. Flynn
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - P.L. Wiesenfeld
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - T.F.X. Collins
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| | - R.K. O'Neilll
- Office of the Scientific Analysis and Support, Laurel, MD 20708, USA
| | - P. Sapienza
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment
| |
Collapse
|
3
|
Final Report of the Safety Assessment of Cosmetic Ingredients Derived From Zea Mays (Corn). Int J Toxicol 2011; 30:17S-39S. [DOI: 10.1177/1091581811403832] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Many cosmetic ingredients are derived from Zea mays (corn). While safety test data were not available for most ingredients, similarities in preparation and the resulting similar composition allowed extrapolation of safety data to all listed ingredients. Animal studies included acute toxicity, ocular and dermal irritation studies, and dermal sensitization studies. Clinical studies included dermal irritation and sensitization. Case reports were available for the starch as used as a donning agent in medical gloves. Studies of many other endpoints, including reproductive and developmental toxicity, use corn oil as a vehicle control with no reported adverse effects at levels used in cosmetics. While industry should continue limiting ingredient impurities such as pesticide residues before blending into a cosmetic formulation, the CIR Expert Panel determined that corn-derived ingredients are safe for use in cosmetics in the practices of use and concentration described in the assessment.
Collapse
|
4
|
Sahu SC, Wiesenfeld PL, Kim CS, Ross IA, Sapienza PP, Newell R, O'Donnell MW, Flynn TJ. Validation of an in vitro model for assessment of androstenedione hepatotoxicity using the rat liver cell line clone-9. J Appl Toxicol 2008; 28:703-9. [PMID: 18059068 DOI: 10.1002/jat.1325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Androstenedione, a naturally occurring steroid hormone, has been used to enhance athletic performance. Little is known, however, about its hepatotoxicity. Clone-9 cells, a non-transformed epithelial cell line that was originally isolated from normal liver of a 4-week old Sprague-Dawley rat, were used as an in vitro model to assess the hepatotoxic potential of androstenedione. The cultures were treated with androstenedione for 24 h at 37 degrees C in 5% CO(2) at concentrations of 0-100 microg ml(-1). After the treatment period, the cells and the culture supernatants were assayed for markers of cytotoxicity which included: release of liver enzymes, cell viability, cellular double-stranded DNA content, oxidative stress, steatosis, cellular ATP content, caspase-3 activity, the mitochondrial permeability transition and induction of cytochrome P450 activity. Significant concentration-dependent differences from control were observed in some endpoints at medium concentrations of 10 microg ml(-1) and above. These in vitro findings were compared with comparable endpoints obtained from an in vivo study of androstenedione toxicity in female Sprague-Dawley rats. Of the eight endpoints that could be compared between the two studies, only three (lipid accumulation, ATP depletion and P450 activity) appeared to be concordant. This suggests that, under the experimental conditions used, the clone-9 cells were not a good model for androstenedione hepatotoxicity.
Collapse
Affiliation(s)
- Saura C Sahu
- Division of Toxicology, Office of Applied Research and Safety Assessment, U. S. Food and Drug Administration, Laurel, MD 20708, USA.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Wiesenfeld PW, Sapienza PP, Flynn TJ, Ford CE, Ross IA, Sahu S, Kim CS, O'Donnell MW, Collins TFX, Sprando RL. Effects of oral androstenedione on phospholipid fatty acids, ATP, caspase-3, prostaglandin E(2) and C-reactive protein in serum and livers of pregnant and non-pregnant female rats. Food Chem Toxicol 2005; 44:579-87. [PMID: 16289525 DOI: 10.1016/j.fct.2005.09.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2005] [Revised: 09/12/2005] [Accepted: 09/25/2005] [Indexed: 11/23/2022]
Abstract
Androstenedione, a steroidal dietary supplement taken to enhance athletic performance, could affect serum and liver lipid metabolism, induce liver toxicity or alter inflammatory response depending on dose and duration of exposure. Pregnancy could further exaggerate these effects. To examine this, mature female rats were gavaged with 0, 5, 30 or 60 mg/kg/day androstenedione beginning two weeks prior to mating and continuing through gestation day 19. Non-pregnant female rats were gavaged over the same time frame with 0 or 60 mg/kg/day androstenedione. Serum was collected and livers were removed from dams on gestation day 20 and from non-pregnant rats after 5 weeks of treatment. Androstenedione had no effect on serum total cholesterol, triglycerides or HDL-cholesterol, but significantly decreased C-reactive protein in pregnant rats and prostaglandin E(2) in serum of both pregnant and non-pregnant rats. There were treatment related decreases in liver ATP and, to a lesser degree, caspase-3 and no change in alkaline phosphatase of pregnant female rats. Androstenedione decreased docosahexaenoic acid in both serum and liver phospholipids of pregnant female rats. In conclusion, oral androstenedione did not result in overt hepatotoxicity in pregnant female rats, but produced modest changes in lipid metabolism and may impair regeneration of injured hepatic cells or tissue.
Collapse
Affiliation(s)
- P W Wiesenfeld
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, 8301 Muirkirk Road, Laurel, MD 20708, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Flynn TJ, Sapienza PP, Wiesenfeld PW, Ross IA, Sahu S, Kim CS, O'Donnell MW, Collins TFX, Sprando RL. Effects of oral androstenedione on steroid metabolism in liver of pregnant and non-pregnant female rats. Food Chem Toxicol 2005; 43:537-42. [PMID: 15721200 DOI: 10.1016/j.fct.2004.12.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2004] [Revised: 12/03/2004] [Accepted: 12/12/2004] [Indexed: 12/16/2022]
Abstract
It is unknown whether androstenedione, a steroidal dietary supplement taken to enhance athletic performance, can affect physiological hormone levels by altering liver enzyme activities that metabolize steroid hormones. Altered hormone levels could be especially devastating during pregnancy. Mature female rats were gavaged with 0, 5, 30 or 60 mg/kg/day androstenedione beginning two weeks prior to mating and continuing through gestation day 19. Non-pregnant female rats were gavaged over the same time frame with 0 or 60 mg/kg/day androstenedione. Livers were removed from dams on gestation day 20 and from non-pregnant rats after five weeks' treatment. Liver microsomes were incubated with 200 microM testosterone, and the reaction products were isolated and analyzed by HPLC. In pregnant rats, formation of 6alpha-, 15beta-, 7alpha-, 16beta-, and 2beta-hydroxytestosterone was increased significantly vs. control at the highest dose level only. Formation of 6beta-hydroxytestosterone increased significantly at both the 30 and 60 mg/kg/day dose levels. In non-pregnant rats, 60 mg/kg/day androstenedione significantly increased formation of 15beta-, 6beta-, 16beta-, and 2beta-hydroxytestosterone. The data suggest that high oral doses of androstenedione can induce some female rat liver cytochromes P450 that metabolize steroid hormones and that the response to androstenedione does not differ between pregnant and non-pregnant female rats.
Collapse
Affiliation(s)
- T J Flynn
- US FDA, Center for Food Safety and Applied Nutrition, Office of Applied Research and Safety Assessment, 8301 Muirkirk Road, Laurel, MD 20708, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|